Iaso Ventures
Venture capitalCambridge · Seed–Series A · 10 people tracked
Also known as IASO VENTURES MANAGEMENT FIRM LLC
Investment thesis
Iaso Ventures invests in game-changing life sciences and healthcare startups working to cure disease and improve patient outcomes. The firm backs data-driven enabling technologies and platforms that support next-generation therapeutic development. Drawing on an investor-operator background and a collaborative, industry-wide approach, Iaso leverages deep sector expertise to accelerate growth and create value. Its mission centers on pursuing the bleeding edge of healthcare innovation while staying grounded in serving patients and maximizing well-being.
Source: firm website, verified Aug 25, 2026.
Team · 10 people
from the firm's website
What they invest in
from 17 of 26 portfolio companiesBiotech ×12Healthtech ×12Medical Devices ×7AI & Machine Learning ×5Deep Tech ×5Digital Health ×4Data & Infrastructure ×3SaaS ×3
HQs:United States×13Canada×1
Who they back
founder profiles across 13 portfolio companiesFounding team size:solo founder×52 founders×63 founders×2
Accelerator rootsportfolio companies that came through a program
Investments · 26 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 12021 · 14 dated
Certara provides biosimulation software, modeling, and regulatory services that support drug discovery and development across discovery, preclinical, clinical, regulatory, and market access phases.
AI & Machine LearningBiotechHealthtechSaaSRadnor, US
John Gallagher III(SVP and Chief Financial Officer)Adrian McKemey(President, Certara Drug Development Solutions)Rona Anhalt(Chief Human Resources Officer)inDaniel Corcoran(SVP and General Counsel)Robert Aspbury(President, Certara Predicitive Technologies)Leif Pedersen(President, Chief Commercial Officer)
Board seatJohn Reynders· per SEC Form D · filed Apr 2026
Co-investorsArsenal
BiotechCambridge, US
Benjamin Cravatt(Manager)James P. Pearson(PRESIDENT, CHIEF EXECUTIVE OFFICER, CHIEF SCIENCE OFFICER)Eduardo J. Martinez(Vice President)
BoardNabil Elkouh(Director)Eric R Olson(Director)Michael F. Higgins(Director)
Board seatMark G. Currie· per SEC Form D · $1.7M raise · filed May 2026
Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.
BiotechDeep TechHealthtechMedical Devices
Stuart Milstein(Co-Founder)Jack O’Meara(Cofounder)in
Co-investorsage1BlueYard CapitalEntrepreneur FirstPsyMed VenturesUnruly CapitalAda Ventures
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsvenBio PartnersMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture Partners+7 more
Boston, US
Jacob A. Donoghue, M.D., Ph.D.(Executive Officer, Director)Jarrett Revels(Executive Officer)Jacob A. Donoghue(Executive Officer, Director, Promoter)
BoardCaitlin Donovan(Director)Pavel Raifeld(Director)Naveen Rao(Director)
Co-investorsCatalio Capital Management, LPGeneral CatalystGV (Google Ventures)Kicker VenturesCasdin CapitalIndicator Ventures+1 more
Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.
BiotechDigital HealthHealthtechMedical DevicesSammamish, US
Kent Leyde(Executive Officer, Director, Promoter)inWarren Douglas Sheffield(Executive Officer, Director, Promoter)
Co-investorsJAZZ Venture PartnersLumira VenturesAngelini VenturesF-Prime Capital
Catena develops a conjugation platform for antibody-drug conjugates (ADCs) and multi-payload conjugates used in oncology for solid tumors.
BiotechDeep TechHealthtechMedical DevicesSan Francisco, US
Marco Lobba(Founder)inMatthew Francis(Founder)in
Co-investorsCivilization Ventures Management, LlcY CombinatorAxial VCLongeVCMBX CapitalSocial Impact Capital
Data & InfrastructureHealthtechPasadena, US
Wout Brusselaers(Executive Officer, Director)inSondra Pepe(Executive Officer)inChristian Duvall(Executive Officer)inAntonia Holway(Executive Officer)inDoug Cassidy(Executive Officer)inPeter Casasanto(Executive Officer)in
Co-investorsInformed Ventures Advisors, LlcPoint72 VenturesTechstarsTMC Venture Fund
EpiWatch is an FDA-cleared seizure detection app for Apple Watch that monitors for tonic-clonic seizures and sends real-time alerts to users and their caregivers.
Digital HealthHealthtechMedical DevicesBaltimore, US
Nathan Crone(Executive Officer, Director, Promoter)Gregory Krauss(Executive Officer, Director, Promoter)Teresa Prego(Executive Officer, Director)Dean Papadopoulos(Executive Officer, Director, Promoter)
BoardDaniel Hanley(Director)Richard Schmitt(Director)
Co-investorsMaryland TEDCOTEDCO
BiotechWeston, US
Nancy Hsiung(Executive Officer)Charles Keough(Executive Officer, Director)Valentin Gribkoff(Executive Officer, Director)
Co-investorsInvivo Capital PartnersSunstone Capital
Neuraura Biotech develops proprietary 3D micro-electrode and microsensor technology for high-fidelity neural recording and percutaneous stimulation, used to improve diagnostic and therapeutic solutions for neurological, psychiatric and sensory conditions.
BiotechFemTechHealthtechMedical DevicesCalgary, CA
Claire Dixon(CEO & Co-Founder)Pierre Wijdenes(CPO & Co-Founder)in
Co-investorsStartup TNTBoxOne Ventures
Neurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders.
BiotechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Executive Officer)inArnold Kriegstein(Director)
BoardPeter Svennilson(Director)inTim Kutzkey(Director)Ray Kelleher(Director)
Co-investorsBerkeley FrontierThe Column GroupYsios CapitalAlexandriaFidelity InvestmentsLYFE Capital+7 more
Co-investors3CC | Third Culture CapitalGood AI CapitalHike Ventures
Prudentia provides an AI-based scientific intelligence platform for life sciences dealmaking, combining expert-developed diligence frameworks, a unified evidence base, and AI reasoning to evaluate drug development assets.
AI & Machine LearningBiotechHealthtech
Co-investorsMcKesson VenturesVirtue Ventures
Ryght AI provides an artificial intelligence-powered platform that uses digital twin technology to help clinical research organizations and sponsors identify and select optimal sites for clinical trials.
AI & Machine LearningBiotechHealthtechMedical Devices
Dr. Chadi Nabhan(Chief Medical Officer)Tom Pike(President and Chief Executive Officer)
Co-investorsAIX VenturesFoothill VenturesPage One VenturesVirtue VenturesLDV PartnersTop Harvest Capital
Statcounter provides website analytics and visitor tracking software that displays traffic data, user behavior, and engagement metrics in a simple interface.
AdTechData & InfrastructureMarketing TechSaaS
Aodhán Cullen(Founder and CEO)
Co-investorsGabriel Venture PartnersHomegrown CapitalHuangpu River CapitalKumpulan Modal PerdanaNucleation CapitalNventure+2 more
Tuva provides infrastructure and data standardization solutions for healthcare analytics teams, enabling them to transform raw healthcare data into analysis-ready datasets.
AI & Machine LearningData & InfrastructureDigital HealthHealthtechSaaSSalt Lake City, US
Aaron Neiderhiser(Founder)inCoco Zuloaga(Founder)in
Co-investorsVirtue VenturesY Combinator
Zafrens develops a unified drug discovery platform that integrates isolation, imaging, and sequencing workflows to accelerate the identification of therapeutic compounds across modalities.
AI & Machine LearningBiotechDeep TechSan Diego, US
Martin SmrcinainMaina NdunguinSwamy Vijayan(Executive Officer, Director)inYi ZhanginVikas Goelin
BoardJustin Briggsin
Co-investorsAcequia Capital (AceCap)BlueYard CapitalGlobal BrainHAWKTAILRaptor GroupFoundersX Ventures+2 more
Zeto develops improved electroencephalography technology for diagnosing epilepsy and other neurological conditions.
Cloud ComputingDeep TechDigital HealthHealthtechMedical DevicesSan Francisco, US
Aswin Gunasekar(Founder and CEO)in
Co-investorsAphelion Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioCertaraNASDAQ: CERT
Portfolio news
latest coverage across their companiesBeacon Biosignals · finance.yahoo.com · Apr 7, 2026
Tuva Health · outofpocket.health · Mar 23, 2026
Ryght · indianweb2.com · Dec 13, 2025
Frequently asked questions
- How many investments has Iaso Ventures made?
- Iaso Ventures has 24 tracked investments, including 1 dated in the last 24 months.
- What stage does Iaso Ventures invest at?
- Iaso Ventures invests at the Seed, Series A stages.
- What sectors does Iaso Ventures focus on?
- Iaso Ventures focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Iaso Ventures located?
- Iaso Ventures is headquartered in Cambridge, US.
- Who does Iaso Ventures co-invest with?
- Iaso Ventures most often shares deals with Virtue Ventures, BlueYard Capital, Civilization Ventures Management, Llc, among 52 tracked co-investors.
Co-investors · 1
Pioneer Fund is a venture capital firm investing in the top Y Combinator startups.
Firms observed investing alongside Iaso Ventures, from public investor directories. Shared companies are the overlap with Iaso Ventures's recorded portfolio.
Similar investors
Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Averin Capital is an investment firm focused on the intersection of technology and health, backing teams building companies in areas such as early disease detection, treatment delivery, personalized care, and medical breakthroughs.
Casdin Capital is an investment firm focused on the life sciences, investing across healthcare, biotechnology, synthetic biology, and related technology.